Post-Crisis, Switzerland Likely To ‘Repatriate’ BioPharm Manufacturing

Biotech Trade Head Foresees Rising 'Swiss Made' Trend

In a post-COVID-19 world, Switzerland’s thriving life sciences sector will be supported by increased domestic manufacturing and production capacity, a sector expert says.

Swiss_Made_Stamp
Swiss biotech and pharma exports already comprise 40% of the total • Source: Shutterstock

Switzerland’s booming, diversified biopharma ecosystem will emerge even stronger and interactive in the post-COVID-19, supported by increased domestic manufacturing capacity built in part to avoid globalization pitfalls laid bare by the pandemic, according to Michael Altorfer who heads the Swiss Biotech Association.

Altorfer told Scrip that the Swiss life sciences industry – which currently generates 40% of Switzerland’s exports - will also...

More from Business

More from Scrip